Non-alcoholic fatty liver disease (NAFLD) can be effectively treated by weight loss, but identifying the underlying responsible mechanisms has been difficult because of the multifactorial pathophysiology. Quantitative systems pharmacology (QSP) approaches can help overcome this challenge. We developed NAFLDsym, a novel QSP model of NAFLD originally derived from DILIsym, and used it to identify specific mechanisms that may be responsible for reductions in liver triglycerides (TG).
American Society for Clinical Pharmacology and Therapeutics (ASCPT), March 15-18, 2017, Washington, DC
By Scott Q Siler, Grant Generaux, Brett A Howell, Paul B Watkins